Exposure-Response to SC Ustekinumab In Moderate-Severe Crohn's Disease: Results From the IM-UNITI Maintenance Study

被引：1
|
作者：
Adedokun, Omoniyi J. [1 ]
Xu, Zhenhua [1 ]
Gasink, Christopher [2 ]
Jacobstein, Douglas [1 ]
Szapary, Philippe [1 ]
Johanns, Jewel [1 ]
Gao, Long Long [2 ]
Davis, Hugh M. [1 ]
Hanauer, Stephen [3 ]
Feagan, Brian G. [4 ]
Ghosh, Subrata [5 ]
Sandborn, William J. [6 ]
机构：
[1] Janssen Res & Dev LLC, Spring House, PA USA
[2] Janssen Sci Affairs LLC, Horsham, PA USA
[3] Northwestern Univ, Feinberg Sch Med, Evanston, IL USA
[4] Western Univ, Robarts Res Inst, London, ON, Canada
[5] Inst Translat Med, Birmingham, W Midlands, England
[6] Univ Calif, La Jolla, CA USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2017年 / 112卷
关键词：
D O I：
10.14309/00000434-201710001-00660
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
660
引用
收藏
页码：S365 / S365
页数：1
相关论文
共 50 条
  • [41] GENOME-WIDE ASSOCIATION STUDY OF BASELINE DISEASE CHARACTERISTICS AND RESPONSE TO USTEKINUMAB IN MODERATE TO SEVERE CROHN'S DISEASE
    Hart, Amy
    Li, Katherine
    Gasink, Christopher
    Jacobstein, Douglas
    Brodmerkel, Carrie
    GASTROENTEROLOGY, 2017, 152 (05) : S985 - S985
  • [42] Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease
    Adedokun, Omoniyi J.
    Xu, Zhenhua
    Gasink, Christopher
    Kowalski, Ken
    Sandborn, William J.
    Feagan, Brian
    CLINICAL THERAPEUTICS, 2022, 44 (10) : 1336 - 1355
  • [43] Molecular response to ustekinumab in moderate-to-severe Crohn's disease by serum protein and biopsy gene expression analysis: results from Ustekinumab phase 3 studies
    Li, K.
    Hayden, K.
    Wadman, E.
    Bhagat, S.
    Emrich, S.
    Jacobstein, D.
    Gasink, C.
    Brodmerkel, C.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S57 - S58
  • [44] MOLECULAR RESPONSE TO USTEKINUMAB IN MODERATE-TO-SEVERE CROHN'S DISEASE BY SERUM PROTEIN AND BIOPSY GENE EXPRESSION ANALYSIS: RESULTS FROM USTEKINUMAB PHASE 3 STUDIES
    Li, Katherine
    Hayden, Karen
    Wadman, Eric
    Bhagat, Sunita
    Emrich, Scott
    Jacobstein, Douglas
    Gasink, Christopher
    Brodmerkel, Carrie
    GASTROENTEROLOGY, 2017, 152 (05) : S986 - S986
  • [45] Efficacy of mirikizumab in comparison to ustekinumab in patients with moderate to severe Crohn's disease: Results from the phase 3 VIVID 1 study
    Jairath, V.
    Sands, B. E.
    Bossuyt, P.
    Farraye, F.
    Ferrante, M.
    Hisamatsu, T.
    Kaser, A.
    Kierkus, J.
    Laharie, D.
    Reinisch, W.
    Siegmund, B.
    Bragg, S. M.
    Hon, E.
    Lin, Z.
    Lopes, M. Ugolini
    Morris, N.
    Protic, M.
    Danese, S.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I62 - I64
  • [46] Re-Induction of Intravenous, Weight-Based Ustekinumab Is Well Tolerated in Patients With Moderate-Severe Crohn's Disease
    Lee, Scott D.
    Kamp, Kendra
    Clark-Snustad, Kindra
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S339 - S340
  • [47] Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease
    Vande Casteele, N.
    Feagan, B. G.
    Vermeire, S.
    Yassine, M.
    Coarse, J.
    Kosutic, G.
    Sandborn, W. J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (02) : 229 - 237
  • [48] Pharmacokinetics and exposure-response relationship of ustekinumab, a human monoclonal antibody to interleukin 12/23, in patients with moderateto-severe Crohn's disease
    Fasanmade, Adedigbo A.
    Adedokun, Omoniyi J.
    Johanns, Jewel R.
    Zhou, Honghui
    Davis, Hugh M.
    Blank, Marion
    GASTROENTEROLOGY, 2008, 134 (04) : A490 - A490
  • [49] Ustekinumab Improves General Health Status and Disease-Specific Health Related Quality of Life of Patients with Moderate to Severe Crohn's Disease: Results from the UNITI and IMUNITI Phase 3 Clinical Trials
    Sands, Bruce E.
    Han, Chenglong
    Gasink, Christopher
    Szapary, Philippe
    Gao, Long-Long
    Lang, Yinghua
    Feagan, Brian G.
    GASTROENTEROLOGY, 2016, 150 (04) : S1004 - S1004
  • [50] Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's disease
    Hu, Chuanpu
    Adedokun, Omoniyi J.
    Chen, Yang
    Szapary, Philippe O.
    Gasink, Christopher
    Sharma, Amarnath
    Zhou, Honghui
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 (05) : 425 - 436
12345